Shionogi strives constantly to supply the best possible medicine (health care solutions) to protect the health and wellbeing of the patients we serve. As a pharmaceutical company, we are focusing on SDGs (Sustainable Development Goals) Goal 3 : “Good health and well-being”. Formulation of “Shionogi global health access policy” is our determination to increase global health care access.

Shionogi as a leading company in infectious disease, has been conducting infectious diseases R&D for more than 60 years. Shionogi is committed to “protect people worldwide from the threat of infectious diseases” as our key focus. We are not limiting ourselves to the research and development of therapeutics for HIV, influenza and antimicrobial resistance, but are also pursuing total care for infectious diseases, through pre-symptomatic, awareness building, prevention, diagnosis, and addressing exacerbations, as well as the treating the infection itself. Shionogi has a group vision towards 2030 “building innovation platforms realizing total care by providing healthcare as a service” so that we can create the future of health care.